CCM
APLS

Cinctive Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Cinctive Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-15,000
Closed -$494K – 538
2021
Q3 		$494K Buy
+15,000
New +$843K 0.02% 454

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Cinctive Capital Management's APLS Position: Q3 2025 in Review

Cinctive Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q3 2025, closing a stake of 47,700 shares — an estimated $826K sold.

Cinctive Capital Management first reported a position in APLS in Q3 2021 and held it in 9 quarters. The position peaked at $2.78M in Q4 2024. 273 funds tracked by Wall St. Rank hold APLS as of Q3 2025.

  • Cinctive Capital Management reported no remaining Apellis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 47,700 Apellis Pharmaceuticals shares in Q3 2025, an estimated $826K.
  • Cinctive Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 9 quarters.
  • Cinctive Capital Management's Apellis Pharmaceuticals position peaked at $2.78M in Q4 2024.
  • 273 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q3 2025.

Based on Cinctive Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.